^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Pancreatic Cancer
    Drug:setidegrasib (ASP3082) (KRAS G12D degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase 2, Multicenter, Open label, Platform Study investigating ASP3082 in patients with Metastatic/Locally Advanced Non-Small-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), with biomarker analysis to characterize response/resistance (UNLOCK ASP3082)

    Excerpt:
    ......
    Trial ID:
    2025-522533-54-00
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-NCI-EORTC 2022
    Title:

    ASP3082, a First-in-class novel KRAS G12D degrader, exhibits remarkable anti-tumor activity in KRAS G12D mutated cancer models

    Published date:
    10/12/2022
    Excerpt:
    ...ASP3082 showed the growth inhibitory activity of KRAS G12D-mutated pancreatic cancer cells, but not of KRAS wildtype cancer cells.